Symptom-based controller therapy

A new paradigm for asthma management

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Appropriate management of persistent asthma, according to US and international guidelines, requires daily use of controller medications, most generally, inhaled corticosteroids (ICS). This approach, although effective and well established, imposes burdens of treatment and side effects onto asthma patients. A growing body of evidence suggests that patients with persistent asthma need not be managed with daily ICS, but rather can use them on an intermittent basis, occasioned by the occurrence of symptoms sufficient to warrant treatment with a rescue inhaler. Large, randomized, controlled studies, over a range of asthma severity, and in a range of ages from pediatrics to adults, suggest that, in well-selected patients, a symptom-based approach to administering controller therapy may produce equivalent outcomes, while reducing exposure to ICS. The concept of providing anti-inflammatory treatment to the patient, at the time inflammation is developing, is termed 'temporal personalization'. The evidence to date suggests that symptom-based controller therapy is broadly useful in selected asthma patients, and is a management approach that could be incorporated into US and international guidelines for asthma.

Original languageEnglish (US)
Pages (from-to)427-433
Number of pages7
JournalCurrent Allergy and Asthma Reports
Volume13
Issue number5
DOIs
StatePublished - Oct 2013

Fingerprint

Asthma
Adrenal Cortex Hormones
Therapeutics
Guidelines
Nebulizers and Vaporizers
Anti-Inflammatory Agents
Pediatrics
Inflammation

Keywords

  • Asthma
  • Inhaled corticosteroids
  • Management
  • Symptom-based controller therapy
  • Treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Symptom-based controller therapy : A new paradigm for asthma management. / Divekar, Rohit; Ameredes, Bill; Calhoun, William.

In: Current Allergy and Asthma Reports, Vol. 13, No. 5, 10.2013, p. 427-433.

Research output: Contribution to journalArticle

@article{c000b3af734248eea54aed7448f4ca03,
title = "Symptom-based controller therapy: A new paradigm for asthma management",
abstract = "Appropriate management of persistent asthma, according to US and international guidelines, requires daily use of controller medications, most generally, inhaled corticosteroids (ICS). This approach, although effective and well established, imposes burdens of treatment and side effects onto asthma patients. A growing body of evidence suggests that patients with persistent asthma need not be managed with daily ICS, but rather can use them on an intermittent basis, occasioned by the occurrence of symptoms sufficient to warrant treatment with a rescue inhaler. Large, randomized, controlled studies, over a range of asthma severity, and in a range of ages from pediatrics to adults, suggest that, in well-selected patients, a symptom-based approach to administering controller therapy may produce equivalent outcomes, while reducing exposure to ICS. The concept of providing anti-inflammatory treatment to the patient, at the time inflammation is developing, is termed 'temporal personalization'. The evidence to date suggests that symptom-based controller therapy is broadly useful in selected asthma patients, and is a management approach that could be incorporated into US and international guidelines for asthma.",
keywords = "Asthma, Inhaled corticosteroids, Management, Symptom-based controller therapy, Treatment",
author = "Rohit Divekar and Bill Ameredes and William Calhoun",
year = "2013",
month = "10",
doi = "10.1007/s11882-013-0375-7",
language = "English (US)",
volume = "13",
pages = "427--433",
journal = "Current Allergy and Asthma Reports",
issn = "1529-7322",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Symptom-based controller therapy

T2 - A new paradigm for asthma management

AU - Divekar, Rohit

AU - Ameredes, Bill

AU - Calhoun, William

PY - 2013/10

Y1 - 2013/10

N2 - Appropriate management of persistent asthma, according to US and international guidelines, requires daily use of controller medications, most generally, inhaled corticosteroids (ICS). This approach, although effective and well established, imposes burdens of treatment and side effects onto asthma patients. A growing body of evidence suggests that patients with persistent asthma need not be managed with daily ICS, but rather can use them on an intermittent basis, occasioned by the occurrence of symptoms sufficient to warrant treatment with a rescue inhaler. Large, randomized, controlled studies, over a range of asthma severity, and in a range of ages from pediatrics to adults, suggest that, in well-selected patients, a symptom-based approach to administering controller therapy may produce equivalent outcomes, while reducing exposure to ICS. The concept of providing anti-inflammatory treatment to the patient, at the time inflammation is developing, is termed 'temporal personalization'. The evidence to date suggests that symptom-based controller therapy is broadly useful in selected asthma patients, and is a management approach that could be incorporated into US and international guidelines for asthma.

AB - Appropriate management of persistent asthma, according to US and international guidelines, requires daily use of controller medications, most generally, inhaled corticosteroids (ICS). This approach, although effective and well established, imposes burdens of treatment and side effects onto asthma patients. A growing body of evidence suggests that patients with persistent asthma need not be managed with daily ICS, but rather can use them on an intermittent basis, occasioned by the occurrence of symptoms sufficient to warrant treatment with a rescue inhaler. Large, randomized, controlled studies, over a range of asthma severity, and in a range of ages from pediatrics to adults, suggest that, in well-selected patients, a symptom-based approach to administering controller therapy may produce equivalent outcomes, while reducing exposure to ICS. The concept of providing anti-inflammatory treatment to the patient, at the time inflammation is developing, is termed 'temporal personalization'. The evidence to date suggests that symptom-based controller therapy is broadly useful in selected asthma patients, and is a management approach that could be incorporated into US and international guidelines for asthma.

KW - Asthma

KW - Inhaled corticosteroids

KW - Management

KW - Symptom-based controller therapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84885174984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885174984&partnerID=8YFLogxK

U2 - 10.1007/s11882-013-0375-7

DO - 10.1007/s11882-013-0375-7

M3 - Article

VL - 13

SP - 427

EP - 433

JO - Current Allergy and Asthma Reports

JF - Current Allergy and Asthma Reports

SN - 1529-7322

IS - 5

ER -